Please type a plus sign (+) inside this box

#9

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known Application Number 09/619,493 NFORMATION DISCLOSURE July 19, 2000 Filing Date STATEMENT BY APPLICANT First Named Inventor N. Nashed et al. Group Art Unit 1616 (use as many sheets as necessary) **Examiner Name** S. Qazi 3 SCH 1686 C1 Sheet Attorney Docket Number

				_		U.S. F	PATENT D	OCUMI	ENTS				<u>r</u>
Examiner Initials *	Cite No.1	\\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	U.S. Pa	Kind (ode ²	Name of I	Patentee or App Cited Document		Date of Publication of Cited Document	of	Pages, Columns, Li Passages Figures	nes, Where or Relevar s Appear	Relevant
		Щ						_					2
		Ш											—— <u> </u>
1		╀	\			<u> </u>							- 12
 	-	+	$\overline{}$			-				-			<u> </u>
-		╁	$\overline{}$							$\overline{}$			
+		+							· - · -	\forall		-	
-	 	+		$\overline{}$						_/			
		1		$\overline{}$									
											1		
		\perp			·			↓.					
		\perp			<u> </u>	ļ					-+		
	-	+			_					-			
+		+			\								
	 	╁								_			
	\	+											
		✝											
	\												
	,	\				FOREIG	PATENT	DOCL	MENTS			L	
Examiner	Cite	\mathcal{I}	For	eign Pa	tent Docur	nent	Name of P	atentee	Date of Publication		Pages, Columns Where Relev	Lines,	
Initials*	No.1		Office ³	Num	ber⁴ K	ind Code ⁵ if known)	or Applic Cited Doc	ant of ument	Cited Docume MM-DD-YYY		Passages or Re Figures App	elevNant	T ₆
												$\overline{}$	
		_	\rightarrow				<u> </u>		ļ.,			$\overline{}$	
		+		ļ			ļ	\					
		-+	-+	<u> </u>									/
		\dashv	/	1				-	 				\vdash
		\dashv		lacktriangledown			 	-					1
		\dashv		\top	-								
				II.									
				Δ									$\overline{}$
Examiner				\	\			Date Consid	larad X				,
Signature					\ .			COLISIO	eren 1				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.

Substitute for form 1449A/PTO

PTO/\$B/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 09/619,493 Filing Date July 19, 2000 N. Nashed et al. First Named Inventor **Group Art Unit** 1616 S. Qazi **Examiner Name** SCH 1686 C1 Attorney Docket Number

(use as many sheets as necessary) of 3 Sheet 3

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	·
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BL	Christine P. West, "Inhibition of ovulation with oral progestins-effectiveness in premenstrual syndrome," European Journal of Obstetrics & Gynecology and Reproductive Biology, 34 (1990), pp. 119-128	
	ВМ	C. Kirkham, MD., et al., "A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial to Assess the Side Effects of Medroxyprogesterone Acetate in Hormone Replacement Therapy," Obstetrics & Gynecology, Vol. 78, No. 1, July 1991, pp. 93-97	
	BN	L. Dennerstein, et al., "Progesterone and premenstrual syndrome: a double blind crossover trial, "British Medical Journal, Vol. 290, June 1, 1985, pp. 1617-1621	
	во	Peter J. Schmidt, MD., et al., "Lack of Effect of Induced Menses on Symptoms in Women with Premenstrual Syndrome," The New England Journal of Medicine, Vol. 324, No. 17, April 25, 1991, pp. 1174-1179	
SOZ	BP	John Bancroft et al., "The Impact of Oral Contraceptives on the Experience of Perimenstrual Mood, Clumsiness, Food Craving and Other Symptoms," Journal of Psychosomatic Research, Vol. 37, No. 2, 1993, pp. 195-202	•
	₿Q	Cynthia A. Graham, et al., "A Prospective Treatment Study of Premenstrual Symptoms Using a Triphasic Oral Contraceptive," Journal of Psychosomatic Research, Vol. 36, No. 3, 1992, pp. 257-266	
	_BR \	Lennart Nilsson et al., "Clinical Studies on Oral Contraceptives-a Randomized, Doubleblind, Crossover Study of 4 Different Preparations (Anovlar® mite, Lyndiol® mite, Ovulen®, and Volidan®)," Acta Obstetrichet Gynecologica Scandinavica," Vol. XLVI, Supplement 8, pp. 2-31	
	BŞ	Johan Cullberg, "Mood Changes and Menstrual Symptoms with Different Gestagen/Estrogen Combinations," Acta Psychiatrica Scandinavica, Supplementum 236, 1972, pp. 9-86	
`	ВТ	Sam Silbergeld, Ph.D., MD., et al., "The Menstrual Cycle: A Double-Blind Study of Symptoms, Mood and Behavior, and Biochemical Variables Using Enovid and Placebo," Psychosomatic Medicine, Vol. 33, No. 5 (Sept-Oct 1971), pp. 411-428	
	-BU	Francis J. Kane, "latrogenic Depression in Women," Phenomenology and Treatment of Depression, Copyright 1977, pp. 69-81	

Examiner Signature	SABIHA	QAZI	Date Considered	//	1/15	102	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

stitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known								
Application Number	09/619,493							
Filing Date	July 19, 2000							
First Named Inventor	N. Nashed et al.							
Group Art Unit	1616							
Examiner Name	S. Qazi							
Attorney Docket Number	SCH 1686 C1							

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS										
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²								
(BAi	Mabray et al., "Treatment of Common Gynecologic-Endocrinologic Symptoms by Allergy Management Procedures," Obstetrics & Gynecology, Vol. 59, No. 5, May 1982, pp. 560-564									
Ob	ВВ	B.P. Appleby, "A Study of Premenstrual Tension in General Practice," British Medical Journal, 2/6/60, pp. 391-393									
	ВС	Stuart L. Smith, "Mood and Menstrual Cycle," pp. 19-59									
-	3 BD	B. Andersch et al., "Progesterone Treatment of Premenstrual Tension-A Double Blind Study," Journal of Psychosomatic Research, Vol. 29, No. 5, 1985, pp. 489-493									
	BE \	Michael A. Richter, M.D., et al., "Progesterone Treatment of Premenstrual Syndrome," Current Therapeutic Research, Vol. 36, No. 5, Nov. 1984, pp. 840-850									
	BF	Gwyneth A Sampson, "Premenstrual Syndrome: A Double-Blind Controlled Trial of Progesterone and Placebo," Brit. J. Psychiat. (1979), 135, 209-215									
009	BG	Sarah Maddocks, et al., "A double-blind placebo-controlled trial of progesterone vaginal suppositories in the treatment of premenstrual syndrome," Am J Obstet Gynecol, March 1986, pp. 573-581									
300 2	вн	Ellen Freeman, et al., "Ineffectiveness of Progesterone Suppository Treatment for Premenstrual Syndrome," JAMA, Vol. 264, No. 3, July 18, 1990, pp. 349-353									
	Bi√	Lorraine Dennerstein, et al., "Treatment of Premenstrual Syndrome a Double-blind Trial of Dydrogesterone," Journal of Affective Disorders, 11 (1986), pp-199-205									
	вл	Gwyneth A. Sampson, et al., "Premenstrual Syndrome A Double-blind Cross-over Study of Treatment with Dydrogesterone and Placebo," British Journal of Psychiatry, 153 (1988), pp. 232-235									
	ВК	Pekka Ylostalo, et al., "Bromocriptine and Norethisterone in the Treatment of Premenstrual Syndrome," Obstetrics & Gynecology, Vol. 58, No. 3, March, 1982, pp. 292-298									

Examiner	CAPIHA	67071	Date	11	115	102
Signature	OMBITH	SHZ1	Considered	<i>"/</i>		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.